A retrospective survey on the safety of Replenine®, a high-purity factor IX concentrate

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 3, 2004, Pages 187-195

  Gascoigne, Ernie W ^a   Dash, C H ^a   Harman, C ^a   Wilmot, D ^a  

^a BIO PRODUCTS LABORATORY   (United Kingdom)

Author keywords

Blood products; Factor IX; Haemophilia B; Pharmacovigilance

Indexed keywords

AMOXICILLIN; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; DICLOFENAC; HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M ANTIBODY; INTERFERON; MONOCLONAL ANTIBODY; PROTHROMBIN COMPLEX; REPLENINE; RIBAVIRIN;

ABDOMINAL DISEASE; ADOLESCENT; ADULT; AGED; ARM DISEASE; ARTICLE; CHILD; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DIZZINESS; DRUG CONTAMINATION; DRUG ERUPTION; DRUG INDUSTRY; DRUG MARKETING; DRUG PURITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; HEADACHE; HEMOPHILIA B; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFUSION; LEG DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NAUSEA; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RETROSPECTIVE STUDY; SCABIES; SKIN IRRITATION; SURGICAL TECHNIQUE; SYNCOPE; TOOTH EXTRACTION; UNCONSCIOUSNESS; UNITED KINGDOM; VIRUS TRANSMISSION;

ADULT; DATA COLLECTION; DEMOGRAPHY; DRUG ADMINISTRATION SCHEDULE; FACTOR IX; FEMALE; GREAT BRITAIN; HEMOPHILIA A; HEMOPHILIA B; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; PATIENT SELECTION; PHARMACOLOGY, CLINICAL; PRODUCT SURVEILLANCE, POSTMARKETING; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SURGICAL PROCEDURES, OPERATIVE; TREATMENT OUTCOME; VIRUS DISEASES;

EID: 1542620762     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.911     Document Type: Article

References (16)

1. Committee for Proprietary Medicinal Products. Note for guidance on the clinical investigation of human plasma derived factor VIII and IX products. CPMP/BPWG/198/95 rev.1. London, 19 October 2000.
2. Palmer L. The history and conduct of safety assessment of marketed medicines studies in the UK. Int J Pharm Med 1998; 12: 181-183.
3. Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? J Roy Coll Physicians London 1995; 29: 41-49.
4. Waller PC, Wood SM, Langman MJS, Breckenridge AM, Rawlins MD. Review of company postmarketing surveillance studies. Br Med J 1992; 304: 1470-1472.
5. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry. Guidelines for company sponsored safety assessment of marketed medicines. Br J Clin Pharmacol 1994; 38: 93-97.
6. Thomas DP, Hampton KK, Dasani H, et al. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. Br J Haematol 1994; 87: 782-788.
7. Thomas DP, Lee CA, Colvin BT, et al. Clinical experience with a highly purified factor IX concentrate in patients undergoing surgical operations. Haemophilia 1995; 1: 17-23.
8. Horowitz B, Prince AM, Hamman J, Watlevicz C. Viral safety of solvent/detergent-treated blood products. Blood Coag Fibrinolysis 1994; 5(Suppl. 3): S21-S28.
9. Gascoigne EW, Dash CH, Harman C, Wilmot D. A new approach to pharmacovigilance in haemophilia: experience with Replenate®, a high-purity factor VIII concentrate. Pharmacoepidemiology and Drug Safety; in press.
10. Karch FE, Lasagna L. Towards the operational identification of adverse drug reactions. Clin Pharmacol Ther 1977; 21: 247-254.
11. ICH Tripartite Guideline. Guideline for good clinical practice. Fed Regist 1997; 62: 25691-25709.
12. UK Haemophilia Centre Directors Organisation. Report on the Annual Returns for 1996. UKHCDO: Oxford, UK, 1998.
13. Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
14. ICH Harmonised Tripartite Guideline. Clinical safety data management - definitions and standards for expedited reporting. Fed Regist 1995; 60: 11284-11287.
15. Foster C, Peacock N. Clinical Confidentiality. Monitor Press: Sudbury, UK, 2000; 2.
16. Appelbaum PS. Threats to the confidentiality of medical records - no place to hide. JAMA 2000; 283: 795-797.